Eagle Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary

Eagle Pharmaceuticals

07/11/2022 14:33

* Eagle Pharmaceuticals Inc  EGRX.OQ  reported quarterly
adjusted
earnings of $1.12​​ per share for the quarter ended in
September. The mean expectation of three analysts for the
quarter was for earnings of 91 cents per share.
    * Revenue rose 65.4% to $65.90 million from a year ago;
analysts
expected $62.08 million. 
    * Eagle Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 27 cents​.
    * The mean earnings estimate of analysts had fallen by
about 50.9%
in the last three months.​ 
    * In the last 30 days one analyst negatively revised an
earnings
estimate 
    * Eagle Pharmaceuticals Inc shares had risen by 19.4% this
quarter and lost 38.0% so far this year.
    * The company reported a quarterly loss of $3.51 million.
    * Wall Street's median 12-month price target for Eagle
Pharmaceuticals Inc is $43.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
7 at 02:32 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      0.91           1.12           Beat
 Jun. 30 2022      3.36           1.56           Missed
 Mar. 31 2022      3.88           4.04           Beat
 Dec. 31 2021      0.94           0.85           Missed